EBGI Category: IBD
-
Is Early Ileocecal Resection for Crohn’s Disease An Appropriate Primary Treatment?
American College of Gastroenterology / EBGI Articles / IBD / Is Early Ileocecal Resection for Crohn’s Disease An Appropriate Primary Treatment?Is Early Ileo-cecal Resection for Crohn’s Disease an Appropriate Primary Treatment? Bharati Kochar, MD, MS Assistant Professor of Medicine,…
-
Low-dose Tricyclic Antidepressants for Irritable Bowel Syndrome: Definitive Evidence of Benefit from ATLANTIS
American College of Gastroenterology / EBGI Articles / IBD / Low-dose Tricyclic Antidepressants for Irritable Bowel Syndrome: Definitive Evidence of Benefit from ATLANTISEditor-in-Chief Dr Philip Schoenfeld looks at a Phase 3 trial published in Lancet of 463 patients with IBS treated with tri-cyclic antidepressant and the effect on a patient’s IBS-Symptom Severity Score.
-
Etrasimod, a Sphingosine 1-Phosphate Receptor Modulator, for Moderate-Severe Ulcerative Colitis: New Options for Oral Therapy
American College of Gastroenterology / EBGI Articles / IBD / Etrasimod, a Sphingosine 1-Phosphate Receptor Modulator, for Moderate-Severe Ulcerative Colitis: New Options for Oral TherapyMultiple treatments for ulcerative colitis are now available. We look at a study published detailing a multi-center, double-blind, placebo-controlled RCT on etrasimod.
-
The New Frontier of Combination Therapy for IBD: The VEGA RCT
American College of Gastroenterology / EBGI Articles / IBD / The New Frontier of Combination Therapy for IBD: The VEGA RCTThe New Frontier of Combination Therapy for IBD: The VEGA RCT Tarun Chhibba, MD1 and Bharati Kochar, MD, MS2 1Advanced…
-
ICYMI: Biosimilar BI 695501 Has Similar Safety and Efficacy to Adalimumab for the Treatment of Crohn’s Disease: VOLTAIRE-CD Study
American College of Gastroenterology / EBGI Articles / IBD / ICYMI: Biosimilar BI 695501 Has Similar Safety and Efficacy to Adalimumab for the Treatment of Crohn’s Disease: VOLTAIRE-CD StudyIn Case You Missed It Biosimilar BI 695501 Has Similar Safety and Efficacy To Adalimumab for the Treatment of Crohn’s…
-
Upadacitinib Is Effective for the Induction and Maintenance of Moderate-to-Severe Crohn’s Disease
American College of Gastroenterology / EBGI Articles / IBD / Upadacitinib Is Effective for the Induction and Maintenance of Moderate-to-Severe Crohn’s DiseaseUpadacitinib Is Effective for the Induction and Maintenance of Moderate-to-Severe Crohn’s Disease Rahul S. Dalal, MD, MPH1 and Jessica R.…
-
Vedolizumab: An EARNEST Option for the Management of Chronic Pouchitis
American College of Gastroenterology / EBGI Articles / IBD / Vedolizumab: An EARNEST Option for the Management of Chronic PouchitisVedolizumab: An EARNEST Option for the Management of Chronic Pouchitis Kristin E. Burke, MD, MPH1,2 and Bharati Kochar, MD, MS…
-
SEAVUE: A Sea of Change in Biologic Positioning for Crohn’s Disease
American College of Gastroenterology / EBGI Articles / IBD / SEAVUE: A Sea of Change in Biologic Positioning for Crohn’s DiseaseSEAVUE: A Sea of Change in Biologic Positioning for Crohn’s Disease Bharati Kochar, MD, MS Division of Gastroenterology, Massachusetts General…
-
ICYMI: Vedolizumab Is Superior to Adalimumab for Clinical Remission and Endoscopic Improvement of Ulcerative Colitis-The VARSITY RCT
American College of Gastroenterology / EBGI Articles / IBD / ICYMI: Vedolizumab Is Superior to Adalimumab for Clinical Remission and Endoscopic Improvement of Ulcerative Colitis-The VARSITY RCTIn Case You Missed It Vedolizumab Is Superior to Adalimumab for Clinical Remission and Endoscopic Improvement of Ulcerative Colitis: The…
-
Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy
American College of Gastroenterology / EBGI Articles / IBD / Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF TherapyACG EBGI: This Evidence-based summary looks at D’Haens G, Panaccione R, Baert F, et al. Risankizumab as Induction Therapy for Crohn’s Disease: Results from the Phase 3 ADVANCE and MOTIVATE Induction Trials. Lancet 2022;399(10340):2015-30.